After marking the milestone of signing 100 oncology practices around the United States, CancerLinQ LLC, the American Society of Clinical Oncology’s (ASCO) nonprofit subsidiary that oversees the development and operation of the CancerLinQ® platform, has announced a number of key partnerships with private technology companies and health associations. CancerLinQ® is a health information technology platform aimed at improving the quality of cancer care using real-world cancer data.
Recent collaborations include:
- An agreement with Tempus and Precision HealthAI to accelerate the development and delivery of high-quality, de-identified clinical data for use by CancerLinQ, its oncologist subscribers, partners, and the broader cancer community. The agreement will also enable CancerLinQ to more quickly build and expand on its core data sharing and quality improvement platform for oncology practices.
- A strategic alliance with the National Society of Genetic Counselors (NSGC), the professional society for genetic counselors. NSGC leaders and members will provide expertise to CancerLinQ to improve the quality of comprehensive clinical care received by patients.
· A collaboration with the Association for Molecular Pathology (AMP), a global, molecular diagnostics professional society. AMP leadership and members will be applying the breadth of their knowledge on how molecular changes in individual tumors can impact cancer treatment.
- A programmatic collaboration with the American College of Medical Genetics and Genomics (ACMG), the medical specialty society for clinical and laboratory genetics professionals. ACMG leadership will provide expertise in medical genetics and genomics focused on preventing, diagnosing, and treating diseases, including cancer.
“Our commitment to oncologists and the patients they serve is stronger than ever. These collaborations will help us deliver cutting-edge clinical tools and enhanced benefits to the cancer centers participating in CancerLinQ,” said CancerLinQ LLC Chief Executive Officer Kevin Fitzpatrick.
CancerLinQ, launched, in part, through support from Conquer Cancer, whose generous donors have helped make the system possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America®; Chan Soon-Shiong Family Foundation; Genentech BioOncology™; HELSINN; Janssen Oncology; Lilly; Raj Mantena, RPh; Novartis Oncology; Pfizer Oncology; Thomas G. Roberts, Jr., MD and Susan M. DaSilva; and Susan G. Komen®.
CancerLinQ® and CancerLinQ Discovery™ are projects of CancerLinQ LLC. For more information on how to participate or partner with CancerLinQ, please visit CancerLinQ.org.